Baird analyst Eric Coldwell raised the firm’s price target on AmerisourceBergen to $199 from $195 and keeps an Outperform rating on the shares. The analyst updated his model for a variety of intraquarter developments including the WBA repurchase, PharmaLex close timing, FX, and boosted EPS estimate modestly.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ABC:
- Billionaire Leon Cooperman Says the Bear Market Is Expected to Continue in 2023 — Here Are 2 ‘Safe Haven’ Stocks That Analysts Like
- DOJ suit shouldn’t create meaningful overhang for AmerisourceBergen, says BofA
- AmerisourceBergen calls DOJ complaint ‘an attempt to shift blame’ from DEA
- The Justice Department Sues AmerisourceBergen (NYSE:ABC). Here’s Why
- Justice Department files civil complaint against AmerisourceBergen over opioids